## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Andrew Cook et al.

Title:

METHOD DETECTING RHEUMATOID ARTHRITIS EMPLOYING THE CB10 PEPTIDE FO MAMMALIAN TYPE II COLLAGEN AS

AN ANTIGEN

Prior Appl. No.: 09/623,497, filed 11/20/2000

Appl. No.:

Unassigned

Filing Date:

February 9, 2004

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56**

Mail Stop PATENT APPLICATION Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. In accordance with 37 CFR §1.98(d)(1), no copy of the listed documents are being provided because they were either cited by applicants, the USPTO, or an examining authority in a corresponding international application.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.

The documents listed on the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding International application. Copies of the documents are not being provided since copies should have been provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO. A copy of the International Search Report setting forth the portion of each reference considered

relevant by the examiner is attached.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date February 9, 2004

FOLEY & LARDNER
Customer Number: 22428

\*22428\* 22428

PATENT TRADEMARK OFFICE Telephone: (202) 672-5404 Facsimile: (202) 672-5399 Stephen A. Bent Attorney for Applicant

Registration No. 29,768

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.

	Substitute for	or form 1449B/PTO		Complete if Known		
	INFORMATI	ON DISCLOSURE	Application Number	Unassigned		
	STATEMEN	T BY APPLICANT	Filing Date	02/09/2004		
	Date Submitte	ed: February 9, 2004	First Named Inventor	Andrew Cook et al.		
	Date Submitte	ed. I ebidaly 9, 2004	Group Art Unit	Unassigned		
(use as many sheets as necessary)			Examiner Name	Unassigned		
Sheet	1	of 5	Attorney Docket Number	017227-0197		

U.S. PATENT DOCUMENTS							
		U.S. Patent I	Document		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
	A1						
	A2						

				F	OREIGN PATENT DOCUMENT	rs		
in	0:4-	Fo	reign Patent Do	cument	Name of Detentes or	Date of Publication of Cited Document	Pages, Columns, Lines,	
Examiner Initials*	Cite No. <sup>1</sup>	Office	<sup>3</sup> Number <sup>4</sup>	Kind Code <sup>5</sup> ( <i>if known</i> )	Name of Patentee or Applicant of Cited Documents	MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T
	B1	JP	62-12800	A	JAPAN	01/21/1987		
	B2							
	B3							$\perp$
	B4							
	B5							1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C1	Andersson, M. A., et al., "Analysis of Type II Collagen Reactive T Cells in the Mouse" Scand. J. Immunol, Vol. 33, pp. 505-510 (1991)	
	C2	Miyahara, H., et al., "Identification and Characterization of a Major Tolerogenic T-cell Epitope of Type II Collagen that Suppresses Arthritis in B10.RIII Mice", Immunology, Vol. 86, pp. 110-115 (1995)	
	C3	Nabozny, G.H., et al., "Identification of a Cyanogen Bromide Fragment of Porcine Type II Collagen Capable of Modulating Collagen Arthritis in B10.RIII (H2 <sup>1)</sup> Mice <sup>1</sup> . Autoimmunity Vol. 20, pp. 39-49	
	C4	Kerwar, S.S., et al., "Type II Collagen Induced Arthritis in Rats: Clinical and Immunological Studies", Int. J. Tiss. Reac. Vol. VII(6), pp. 409-429	
	C5	Rowley, M.J., et al., "Epitope Specificty of Antibodies to Type II Collegan in Rheumatoid Arthritis and Systemic Lupu Erythematosus", Rheumatology International, Vol. 12(2), pp. 65-69.	
	C6	Boissier, M.C., et al., "Role De La Conformation Du Collagene Dans L'Immunite Anti-Collagene De Type II Au Cours De La Polyarthrite Rhumatoide", Revue du Rhumatisme, Vol. 58(1), pp. 19-24 (1991)	
	C7		
	C8		

Examiner	Date	
Signature	Consi	idered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Page 2 of 5

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE		ATTY. DOCKET NO.	SERIAL NO.				
(MODIFIED)		PATENT AND TRADEMARK OFFICE		017227/0197		Unassigned			
•				APPLICANT					
INFO	RMATIC	ON DISCLOSURE (	CITATION	Andrew COOK et al.					
				FILING DATE		GROUP AR	TUNIT		
	(Use se	veral sheets if necess	sary)	02/09/2	004	Una	ssigned		
			U.S. PATEN	T DOCUMENTS					
EXAMINER		DOCUMENT				SUB-	FILING	DATE	
INITIAL	REF	NUMBER	DATE	NAME	CLASS	CLASS	IF   APPRO		
							7111101		
					<u> </u>				
						<u> </u>			
			FOREIGN PAT	ENT DOCUMENTS					
	REF	DOCUMENT	DATE	COUNTRY	CLASS	SUB- CLASS	TRANS		
	KEF	NUMBER	5,2			CLASS	YES	NO	
				<u> </u>					
	1								
	<u>-l —</u>			Author, Title, Date, Pe					
-		Bornstein, P. and S	age, H. (1980). Struc	cturally distinct collager	n Types. Ann. Ro	ev. Biochem.	49:957-100	03.	
		Brodsky, B. and Sh	ah, N.K. (1995). The	triple-helix motif in pro	teins FASEB J.	9:1537-1546			
						<del></del>			
		Buckee, C., Morgan, K., Ayad, S., Collins, I., Clague, R.B., Holt, P.J.L. (1990). Diversity of antibodies to type I collagen in patients with rheumatoid arthritis: detection by binding to –chains and to cyanogen bromide peptides. Brit. J. Rheumatol. 29:254-258						type II	
		Charriere, G., Harti	mann, D.J., Vignon, I en in the serum of pa	E., Ronziere, M-C., Heratients with rheumatic c	rbage D., Ville, O diseases. Arthriti	6. (1988). Anti s Rheum. 31:	bodies to t 325-332.	ypes I,	
		type II collagen; oc	currence in rheumate	V., Bateman, J.F., Cole oid arthritis, other arthri Rheum. Dis. 47:313-32	itides, autoimmu	R. (1988). Au ne connective	toantibodie diseases	es to , and	
							and hime !		
		Clague, R.B., Shave collagen in patients	v, M.J., Holt, P.J.L. ( s with inflammatory a	1980). Incidence of ser orthritis . Ann. Rheum. I	um antibodies to Dis. 39:201-206.	native type I	and type I		
EXAMINER								<del></del>	
EVOIMINER		E CONSIDERED							
*	Draw	MINER: Initial if c Initial if c Ine through cital Inext communicati	tion if not in conf	d, whether or not ci ormance and not c	itation is in co onsidered. In	onformance clude any o	with MP opy of the	EP 609; nis form	

Page 3 of 5

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	SERIAL NO.				
(MODIFIED)	PATENT AND TRADEMARK OFFICE	017227/0197	Unassigned				
,		APPLICANT					
INFORMA	TION DISCLOSURE CITATION	Andrew COOK et al.					
		FILING DATE	GROUP ART UNIT				
(Use	several sheets if necessary)	02/09/2004	Unassigned				
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages	, Etc.)				
	Collier, D.H., Kerwar, S.S., Garovoy, M.R response gene products in rheumatoid an	., Fye, K.H., Stobo, J.D. (1984). Antic rthritis. Arthritis Rheum, 27:1201-1209	ollagen antibodies and immune				
	Cook, A.D., Rowley, M.J., Stockman, A., collagen in early rheumatoid arthritis. J. F		pecificity of antibodies of type II				
	Cook, A.D., Rowley, M.J., Mackay, I.R., Crheumatoid arthritis: correlation with dise	Gough, A., Emery, P. (1996). Antibodio ase progression. Arthritis Rheum 39:1	es to type II collagen in early 720-1727.				
		Courtenay, J.S., Dallman, M.J., Dayan, A.D., Martin, A., Mosedale, B. (1980). Immunization against heterologous type II collagen induces arthritis in mice. Nature 283:666-667.					
	Fujii, K., Tsuji, M., Kitamura, A., Murota, assay in rheumatoid arthritis. Int. Orthop.	K. (1992). The diagnostic significance 16:272-276.	of anti-type II collagen antibody				
	Gay, S., Gay R.E. and Miller, E.J. (1980)	. The collagens of the joint. Arthritis R	heum. 23:937-941.				
	Gioud, M., Meghlaoui, A., Costa, O., Mor by an enzyme linked immunosorbent ass Collagen Rel. Res. 2:557-564.	nier, J.C. (1982). Antibodies of native t say (ELISA) in rheumatoid arthritis and	ype I and II collagens detected I systemic lupus erythematosus.				
	Heinegard, D. and Paulsson, M. (1987).	Methods Enzymol. 145:336-363.					
	Hochberg, M.C. (1981). Adult and Juven Rev. 3:27-44.	ile rheumatoid arthritis: current epiden	niologic concepts. Epidemiol.				
	Miller F. I. (4005). The short are of Shail.	forming colleges Ann N.V. Acad Sc					
	Miller, E.J. (1985). The structure of fibril-	Torming Collagens, Allin, N. 1, Acad. 50	л. тоо. I= Io.				
	Miller, E.J. and Lunde, L.G. (1973). Isola alpha-I(II) chain of bovine and human ca	tion and characterization of the cyano rtilage collagen. Biochem 12:3153-31	gen bromide peptides from the 59.				
	Miller, E.J. and Rhodes, R.K. (1982). Pre Enzymol. 82:33-64.	paration and characterization of the d	ifferent types of collagen. Meth.				
	Morgan, K., Clague, R.B., Collins, I., Aya native and denature cartilage collagens (Rheum. Dis. 46:902-907.	d, S., Phinn, S.D., Holt, P.J.L. (1987). (types II, IX, and XI) and to type I colla	Incidence of antibodies to igen in rheumatoid arthritis. Ann.				
	Morgan, K., Clague, R.B., Collins, I., Aya anticollagen antibodies in patients with rl	id, S., Phinn, S.D., Holt, P.J.L. (1989). neumatoid arthritis. Arthritis Rheum. 3	A longitudinal study of 2:139-145.				

				Page 4 of
orm PTO-144	49	U.S. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	SERIAL NO.
MODIFIED)		PATENT AND TRADEMARK OFFICE	017227/0197	Unassigned
			APPLICANT	
INFO	RMATI	ON DISCLOSURE CITATION	Andrew	COOK et al.
			FILING DATE	GROUP ART UNIT
	(Use s	everal sheets if necessary)	02/09/2004	Unassigned
		OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pa	ages, Etc.)
		Pereira, R.S., Black, C.M., Duance, V.C., antibodies in rheumatoid arthritis. Lancet	Jones, V.E., Jacoby, R.K., Welsi ii:501-502.	n, K.I. (1985) Disappearing collagen
		Piez, K.A. (1976). Primary structure. In B Plenum, New York, pp 1-44.	iochemistry of collagen. Ramchar	ndran, G.H. and Reddi, A.N. (eds).
		Piez, K.A. (1982). Structure and assemb	ly of the native collagen fibril. Con	nect Tissue Res. 10:25-36.
		Rosenberg, A.M., Hunt, D.W.C., Pretty, F children with rheumatic diseases. J. Rhe		and denatured type II collagen in
		Rowley, M.J., Gershwin, M.E., Mackay, I rheumatoid arthritis: differences in levels	R. (1988). Collagen antibodies in and type-specificity. J. Rheumato	juvenile arthritis and adult ol. 15:289-294.
		Rowley, M.J., Mackay, I.R., Brand, C.A., type II collagen in rheumatoid arthritis an	Bateman, J.F., Chan, D. (1992). I d systemic lupus erythematosus.	Epitope specificity of antibodies of Rheumatol. Int. 12:65-69
		Scott, P.G. and Veis, A. (1976) The cyar Connect Tissue Res. 4:107-116.	nogen bromide peotides of bovine	soluble and insoluble collagens.
		Stuart, J.M., Huffstutter, E.H., Townes, A. I, II, III, IV and V collagen in rheumatoid radioimmunoassay. Arthritis Rheum. 26:	arthritis and other rheumatic disea	and specificity of antibodies to type ases as measured by 125 I-
		Steffen, C., Timpl R. (1963). Antigenicity rheumatoid arthritis sera. Int. Arch. Aller	of collagen and its application in gy Appl. Immunol 22:333-349.	the serological investigation of
		Stockman, A., Rowley, M.J., Emery, P., collagen antibodies: a prospective study	Muirden, K.D. (1989). Activity of rl . Rheumatol. Int. 8:239-243	heumatoid arthritis and levels of
		Terato, K. Cremer, M.A., Hasty, K.A., Ka immunological studies of the renatured a collagen. Coll. Rel. Res. 5:469-480.	ing, A.H., Hasty, D.L., Townes, A. alpha I(II) chains and isolated cya	S. (1985). Physicochemical and nogen bromide peptides of type II
		Terato, K., Shimozuru, Y., Katayama, K. Kobayashi, S., Goto, M., Nishioka, K., M collagen in rheumatoid arthritis. Arthritis	liyatsaka, N., Nagai, Y. (1990). Sp	yatsu, M., Fujii, K., Sagara, M., pecificity of antibodies of type II
	1		H. (1977). Autoimmunity to type II	

				Page 5 of 5
Form PTO-14	49	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.
(MODIFIED)		PATENT AND TRADEMARK OFFICE	017227/0197	Unassigned
			APPLICANT	
INFO	RMATI	ON DISCLOSURE CITATION	Andrew COOK	et al.
			FILING DATE	GROUP ART UNIT
	(Use se	everal sheets if necessary)	02/09/2004	Unassigned
		OTHER DOCUMENTS (Including A Trentham, D.E. Kammer, G.M., McCune, of psoriatic and rheumatoid arthritis. Arthritis.	W.J., David, J.R. (1981). Autoimmunit ritis Rheum. 24:1363-1369.	y to collagen. A shared feature
		Werkmeister, J.A., Ramshaw, J.A. M (19) 274:895-898.	91). Multiple antigenic determinants on	type III collagen. Biochem J.
	ł			